Ken Griffin Axsome Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$78.93 - $95.84 $489,366 - $594,208	6,200 Added 8.31%	80,800 $7.26 Million
Q2 2024 Aug 14, 2024	SELL	$65.72 - $80.5 $532,332 - $652,050	-8,100 Reduced 9.79%	74,600 $6.01 Million
Q1 2024 May 15, 2024	SELL	$69.39 - $97.64 $555,120 - $781,120	-8,000 Reduced 8.82%	82,700 $6.6 Million
Q4 2023 Feb 14, 2024	SELL	$57.42 - $83.61 $183,744 - $267,552	-3,200 Reduced 3.41%	90,700 $7.22 Million
Q3 2023 Nov 14, 2023	SELL	$69.25 - $82.21 $3.44 Million - $4.09 Million	-49,700 Reduced 34.61%	93,900 $6.56 Million
Q2 2023 Aug 14, 2023	SELL	$58.41 - $90.35 $3.98 Million - $6.15 Million	-68,100 Reduced 32.17%	143,600 $10.3 Million
Q1 2023 May 15, 2023	SELL	$58.39 - $75.0 $27.9 Million - $35.8 Million	-477,900 Reduced 69.3%	211,700 $13.1 Million
Q4 2022 Feb 14, 2023	SELL	$39.94 - $79.72 $5.76 Million - $11.5 Million	-144,200 Reduced 17.29%	689,600 $53.2 Million
Q3 2022 Nov 14, 2022	BUY	$36.06 - $69.85 $14.7 Million - $28.5 Million	407,500 Added 95.59%	833,800 $37.2 Million

325

37.7M

912K

855K

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $3.89B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.